
Herantis H2 2023 - Presented positive phase I data

Redeye reviews the case of Herantis in the wake of progress with clinical candidate HER-096 and H2 report last week. We reiterate our positive view of the company.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Herantis H2 2023 - Presented positive phase I data](#)